Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

McDonald’s Stock Pushes Onward and Upward With Menu-Tech Acquisition

By Chris Lau, InvestorPlace Contributor

McDonald's $300 million investment in menu-customization tech is a big step in store digitization. That sort of innovation will drive MCD stock to new levels.

Fed Rate Hike Pause Could Pressure Bank of America Stock

By Chris Lau, InvestorPlace Contributor

Interest rate hikes are on pause for now, leading to a decline of BAC stock. The drop of Bank of America stock was overdone.

Facebook Stock Upside: 3 Reasons It’ll Bounce Back To $200 A Share

By Chris Lau, InvestorPlace Contributor

Facebook revenue growth should be fueled by Instagram Stories and News Feed strength. FB stock is not an expensive stock at these levels.

5 Social Media Stocks to Buy Instead of Facebook

By Chris Lau, InvestorPlace Contributor

There are other social media stocks to consider than Facebook. Here are five alternatives that offer interesting opportunities.

What Happens to Tesla Stock After Model Y Launch?

By Chris Lau, InvestorPlace Contributor

News of Tesla's crossover SUV failed to draw TSLA stock investors though the new model could resonate well with consumers

Snap Stock Will Make a Strong Recovery Sooner Than You Think

By Chris Lau, InvestorPlace Contributor

SNAP stock is on fire for two good reasons: an analyst upgrade and a strong Q4 report, making it possible for a longer-term comeback.

Sage Stock Pops on FDA Approval for Postpartum Depression Drug

By Chris Lau, InvestorPlace Contributor

Sage stock is up after the FDA approved its Zulresso, the first ever drug specifically for postpartum depression.

7 Financial Stocks to Invest In Today

By Chris Lau, InvestorPlace Contributor

With the easy money already made and rate hikes slowing in 2019, financial stocks will see moderately good results in the months ahead.

Why NIO Is Not the Tesla of China

By Chris Lau, InvestorPlace Contributor

Despite the large, recent decline of NIO stock, NIO has multiple, upcoming positive catalysts that should boost NIO stock price.

Nike Might Blast Higher After Its Earnings Report

By Chris Lau, InvestorPlace Contributor

Bears are betting against Nike stock ahead of its earnings report. This is despite its digital transformation accelerating growth.

Load More